Back to top
more

Vanda Pharmaceuticals (VNDA)

(Delayed Data from NSDQ)

$5.40 USD

5.40
885,375

-0.24 (-4.26%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $5.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Conatus Stock Up on Liver Drug Collaboration with Novartis

Conatus (CNAT) inked an exclusive option, collaboration and license agreement with Novartis (NVS) for the worldwide development and commercialization of emricasan.

    Agios Stops Development of PKR Activator AG-519, Stock Falls

    Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.

      Ionis (IONS) Receives Milestone Payment from AstraZeneca

      Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.

        Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis

        Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).

          Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

          Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

            Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls

            Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.

              Intercept (ICPT) Ocaliva Gains Conditional Approval in EU

              Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.

                Trovagene to Focus More on Liquid Biopsy Testing Market

                Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.

                  athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017

                  athenahealth Inc. (ATHN) reaffirmed its full-year 2016 guidance and issued a stable guidance for 2017.

                    Intuitive Surgical (ISRG) Raises Share Buyback to $3 Billion

                    Intuitive Surgical Inc. (ISRG) increased the authorized amount available under the company's share repurchase program to $3.0 billion.

                      Envision Healthcare Acquires Desert Mountain Consultants

                      Envision Healthcare Corporation (EVHC), a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc.

                        Proteon Slips to 52-Week Low on Kidney Disease Study Data

                        Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.

                          Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe

                          Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.

                            Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

                            Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

                              Corcept Korlym Positive in Phase I/II Breast Cancer Study

                              Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.

                                Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails

                                Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.

                                  AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

                                  AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

                                    Sage Therapeutics Stock Up on SAGE-547 Regulatory Update

                                    Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.

                                      Theravance Stock Up on Fast Track Status for Velusetrag

                                      Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.

                                        Bristol-Myers Reports Data from Opdivo Combination Studies

                                        Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

                                          GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss

                                          GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).

                                            Novo Nordisk Files Regulatory Application for Semaglutide

                                            Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

                                              Acceleron, Celgene Present Myelodysplastic Syndromes Data

                                              Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

                                                Alnylam Reports Positive Data on Fitusiran, Givosiran

                                                Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

                                                  Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

                                                  Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).